Investigational drug · Phase 3
4-MUST
Also called: trimebutine 4-methylumbelliferyl sulfate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Cholecystitis, Biliary Dyskinesia.
Phase 3Last checked: Nov 19, 2026Latest source record: May 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
654
Any phase or sponsor naming "4-MUST"
First trial start
2024
Oct 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "4-MUST", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Cholecystitis
- Biliary Dyskinesia
Approved drugs for the same conditions: Neurology · Gastroenterology and liver · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "4-MUST" as an intervention, largest first.
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03535558 · 239,306 participants · Start May 17, 2018 · Primary completion Dec 31, 2018
Drug: Fluoroquinolone (FQ); Azithromycin (AZ) and 1 more · For: Bronchitis; Sinusitis; Urinary Tract Infections
Sites: Titusville, New Jersey
- APEX-STROKE Adaptive Platform Trial for StrokePivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07784569 · 20,000 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 30, 2029
Drug: Early Angong Niuhuang Pill Treatment; Yiqi Huayu Jiedu Mixture · For: Stroke
- The Cancer of the Pancreas Screening-5 CAPS5)StudyPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT02000089 · 9,000 participants (planned) · Start Jan 6, 2014 · Primary completion Dec 2028
Drug: Secretin · For: Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation and 2 more
Sites: New Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 9 sites in all
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan AfricaPivotal-lookingRecruiting
Biofabri, S.LIndustry
NCT04975178 · 7,120 participants (planned) · Start Oct 17, 2022 · Primary completion Feb 2029
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
BayerBayer (BAYRY)
NCT00997997 · 6,127 participants · Start Oct 2005 · Primary completion Dec 2008
Drug: Moxifloxacin (Avelox, BAY12-8039) · For: Skin Diseases, Bacterial
Sites: Many Locations, Austria; Many Locations, Bulgaria; Many Locations, Egypt · 12 sites in all
- A Toolbox Approach to Obesity Treatment in Primary CarePivotal-lookingCompleted
Denver Health and Hospital AuthorityAcademic, hospital or other
NCT01922934 · 4,730 participants · Start Jan 2014 · Primary completion Aug 2016
Drug: Obesity pharmacotherapy · For: Obesity
Sites: Denver, Colorado
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)Pivotal-lookingStatus unknown
Trans Tasman Radiation Oncology GroupAcademic, hospital or other
NCT00887380 · 2,023 participants · Start Sep 16, 2009 · Primary completion Dec 2024
Drug: Pre-radiotherapy commencement of anastrozole; Post radiotherapy commencement of anastrozole · For: Breast Cancer
Sites: Canberra, Australia; Campbelltown, Australia; Camperdown, Australia · 34 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
Instituto Nacional de Salud Publica, MexicoAcademic, hospital or other
NCT01717118 · 2,000 participants · Start Nov 2009 · Primary completion Feb 2015
Drug: Bivalent Vaccines; Tetravalent Vaccine · For: Healthy
Sites: Cuernavaca, Mexico
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.